Immunome IMNM Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

Arcus BiosciencesRCUS

-90.8%+373pp

Summit TherapeuticsSMMT

-271%-1,725pp

CytomX TherapeuticsCTMX

-37.8%—

Nektar TherapeuticsNKTR

-53.6%-22.6pp

Gilead SciencesGILD

-20.6%-53.8pp

FAQ

What is Immunome's return on equity?

Immunome (IMNM) reported return on equity of -50.1% in Q1 2026.

How has Immunome's return on equity changed year-over-year?

Immunome's return on equity increased by 27.6% year-over-year, from -69.2% to -50.1%.

What is the long-term trend for Immunome's return on equity?

Over 4 years (2021 to 2025), Immunome's return on equity has grown at a -1.4% compound annual growth rate (CAGR), from -55.2% to -52.1%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.